← 返回

机器学习构建了一个免疫逃逸特征,用于预测肺腺癌的预后和免疫治疗获益

英文原题:Machine learning developed an immune evasion signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.

查看英文原题

Machine learning developed an immune evasion signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.

PubMed 2025/06/19(内容时间) Front Cell Dev Biol Q1 · IF 5.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的研究开发了一种新的 LUAD 患者 IRS,可作为预测预后和免疫治疗反应的指标。

研究思路结论见上方概要

肺腺癌(LUAD)是全球最常见的癌症之一,也是癌症相关死亡的主要原因。免疫治疗的进步扩大了LUAD的治疗选择。然而,LUAD患者的临床结局并未达到预期,这可能与免疫逃逸机制有关。

采用包含十种方法的整合机器学习方法,利用TCGA、GSE72094、GSE68571、GSE68467、GSE50081、GSE42127、GSE37745、GSE31210和GSE30129数据集构建免疫逃逸相关特征(IRS)。通过多种技术分析IRS与肿瘤免疫微环境之间的关系。进行体内实验以研究关键基因的生物学作用。

由Lasso开发的模型被视为可选的IRS,其作为独立危险因素,在预测LUAD患者临床结局方面具有良好的性能。基于IRS的低风险评分表明NK细胞、CD8+ T细胞和免疫激活相关功能水平较高。IRS的C-index高于许多已开发的LUAD特征和临床分期。低风险评分表明肿瘤逃逸评分较低、TIDE评分较低、TMB评分较高以及CTLA4&PD1免疫表型评分较高,提示免疫治疗反应更好。敲低PVRL1通过调控PD-L1表达抑制肿瘤细胞增殖和集落形成。

展开英文摘要原文

Lung adenocarcinoma (LUAD) is one of the most common cancers worldwide and a major cause of cancer-related deaths. The advancement of immunotherapy has expanded the treatment options for LUAD. However, the clinical outcomes of LUAD patients have not been as anticipated, potentially due to immune escape mechanisms.

An integrative machine learning approach, comprising ten methods, was applied to construct an immune escape-related signature (IRS) using the TCGA, GSE72094, GSE68571, GSE68467, GSE50081, GSE42127, GSE37745, GSE31210 and GSE30129 datasets. The relationship between IRS and the tumor immune microenvironment was analyzed through multiple techniques. In vivo experiments were performed to investigate the biological roles of the key gene.

The model developed by Lasso was regarded as the optional IRS, which served as an independent risk factor and had a good performance in predicting the clinical outcome of LUAD patients. Low IRS-based risk score indicated higher level of NK cells, CD8 + T cells, and immune activation-related functions. The C-index of IRS was higher than that of many developed signatures for LUAD and clinical stage. Low risk score indicated had a lower tumor escape score, lower TIDE score, higher TMB score and higher CTLA4&PD1 immunophenoscore, suggesting a better immunotherapy response. Knockdown of PVRL1 suppressed tumor cell proliferation and colony formation by regulating PD-L1 expression.

Our study developed a novel IRS for LUAD patients, which served as an indicator for predicting the prognosis and immunotherapy response.

论文信息

作者
Ding D、Huang G、Wang L、Shi K、Ying J、Shang W、Wang L、Zhang C
第一作者单位
Department of Thoracic Surgery, The People's Hospital of Beilun District, Ningbo, Zhejiang, China.China
通讯作者单位
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.China
期刊
Frontiers in cell and developmental biology2025
原文标识
PubMed 40612112 · DOI 10.3389/fcell.2025.1622345